Hiku Brands Company Ltd. (CSE:HIKU,OTCUS:DJACF), Canada’s first vertically-integrated cannabis brand house, is pleased to announce that it has entered into an exclusive collaboration agreement (the “Agreement”) with Jackman Reinvention Inc. (“Jackman”), a strategic and creative brand consultancy with deep experience in retail execution.

 Headquartered in Toronto, Canada, Jackman is comprised of leading experts across its core disciplines of research, analytics, business strategy, brand strategy, customer experience design, and in-market activation. Jackman’s extensive experience in go-to-market, ongoing learning and growth strategies, in collaboration with HIKU’s industry leading brand house, will help form robust retail presence and meaningful brand differentiation.

Joe Jackman, CEO of Jackman, has extensive experience in retail brand strategy and activation, previously serving as (Acting) Chief Marketing Officer of Duane Reade, EVP, Marketing of Loblaw Companies Ltd. and (Acting) Chief Marketing Officer of Old Navy, Gap Inc. Since Jackman’s inception, Joe has advised the likes of Rexall, Freshco, The Beer Store, Sobeys and Canadian Tire, among other select clientele.


“We are pleased to commence an exclusive collaboration with Joe Jackman and the Jackman Reinvents team” comments Alan Gertner, CEO of Hiku. “This strategic mandate will result in a blueprint for dispensary build-outs in select provinces, with a focus on best in class customer experience. Together we will work to define the modern cannabis retail experience for the world.”

Jackman’s ability to enhance retail customer experience will be leveraged in lock-step with Hiku’s premium brand house market positioning. “We are excited to collaborate with and build upon Hiku’s cannabis retail platform” said Joe Jackman. “We believe in Hiku’s vision and that, together, we will create the leading cannabis retail experience. Our partnership is designed to deliver the most powerful and coordinated go-to-market, all focused on achieving scale with speed.”

Pursuant to the Agreement, Jackman’s services to the cannabis sector will be exclusive to Hiku for twice the length of the Agreement. In connection with the Agreement, the Company has agreed to issue to Jackman $800,000 worth of common shares of the Company, of which 50% will be issued immediately and 12.5% will be issued on each of June 1, 2018, September 1, 2018, December 1, 2018 and March 1, 2019.

About Hiku

Hiku is focused on building a portfolio of iconic, engaging cannabis brands, unsurpassed retail experiences and handcrafted cannabis production. With a national retail footprint led by Tokyo Smoke, craft cannabis production through DOJA‘s ACMPR licensed grow, and Van der Pop‘s female-focused educational platforms, Hiku houses an industry-leading portfolio that sets the bar for cannabis brands in Canada.

Hiku’s wholly-owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. The Company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

Regarding Forward-Looking Information

This news release contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Hiku’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this document include statements regarding the Company’s anticipated results of the collaboration with Jackman, including the build-out of dispensaries in select provinces. By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Hiku is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

For further information: Abigail Van Den Broek, abby@abigailv.ca, 416-799-8510 or visit HIKU’s website at www.hiku.com.

Click here to connect with Hiku Brands Company Ltd. (CSE:HIKU,OTCUS:DJACF) and receive an Investors Presentation.

Source: www.newswire.ca

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less